Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials-Reference-Cited by-同舟云学术

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials

Published:2018-10 Issue:10155 Volume:392 Page:1311-1320
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Willeit Peter,Ridker Paul M,Nestel Paul J,Simes John,Tonkin Andrew M,Pedersen Terje R,Schwartz Gregory G,Olsson Anders G,Colhoun Helen M,Kronenberg Florian,Drechsler Christiane,Wanner Christoph,Mora Samia,Lesogor Anastasia,Tsimikas Sotirios

Funder

National Institutes of Health

NIH

Publisher

Elsevier BV

Subject

General Medicine

Reference40 articles.

1. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies;Tsimikas;J Am Coll Cardiol,2017

2. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis;Tsimikas;J Am Coll Cardiol,2018

3. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans;van der Valk;Circulation,2016

4. MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma;Wiesner;J Lipid Res,2013

5. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a);Leibundgut;J Lipid Res,2013

Cited by 398 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipoprotein(a) and cardiovascular disease;The Lancet;2024-09

2. Correlation between circulating lipoprotein(a) levels and cardiovascular events risk in patients with type 2 diabetes;Heliyon;2024-09

3. Strategies for management of patients with elevated lipoprotein(a);Current Opinion in Lipidology;2024-08-14

4. Lipoprotein(a) in interventional cardiology: identifying patients at highest risk of recurrent cardiovascular events through early recognition – a case based review;Expert Review of Cardiovascular Therapy;2024-08-02

5. Early health technology assessment of gene silencing therapies for lowering lipoprotein(a) in the secondary prevention of coronary heart disease;Journal of Clinical Lipidology;2024-08